Stay updated with breaking news from எவன் சீகர்மேன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Markets Insider Goldman Sachs video game analyst Michael Ng s favorite stock right now is gaming company, Activision Blizzard. It s on Goldman s Americas Conviction list, which represents his department s best ideas. We think that Activision s earnings power is underappreciated by the market and should benefit from a strong pipeline of new games, the expansion on to new platforms – whether that s on mobile or something else – and through new business models, whether that s free to play or subscription. Ng and his team first upgraded Activision Blizzard in May 2019. It s been a great call and we continue to like it here, he said. ....
JPMorgan Equity research is all about being on top of things. The earlier you learn that in your role you have to prioritize, while still keeping an eye on the macro and what s going on in other sectors, that helps you become more well-rounded. You have to be really passionate about the role, which is not very easy. It s kind of like a lifestyle. You have to be passionate about the job, and it s hard to do it really well if you aren t treating it like a lifestyle. - Bank of America Test and retest your assumptions Never allow yourself to get bored, and I think that one is a little bit straightforward in that being a research analyst requires you to be intellectually curious. But the way I approach my job is there s always another angle to look at things. You can continually test and retest your assumptions. ....
Kristen Owen didn t start her career in equity research right away. After graduating from Kent State University in Ohio, she worked at a bank branch in Akron as a financial consultant before deciding to get her MBA at American University. She then worked in wealth management in Washington, DC, for a year, an experience that has helped her stay focused on the impact her equity research has. I think it provided me with a little bit more context to understand that the research I do my clients are mutual-fund managers or hedge-fund managers but ultimately the people who matter in that theme are our parents, our grandparents, Owen said. ....
Share it A single drug has defined Biogen, one of the world s largest biotechnology companies, for the past year and a half. Known as aducanumab, the drug is far from ordinary. It stands a chance of being the first treatment approved to alter the course of Alzheimer s, a disease that impacts millions of lives and is estimated to cost healthcare systems hundreds of billions of dollars each year. The Food and Drug Administration should decide whether to clear aducanumab for market by June 7, and if it votes yes, investors expect a sales windfall for Biogen. Having worked closely with the FDA before submitting a marketing application, Biogen remains confident that its drug will gain approval in spite of controversial results from clinical testing and a decidedly negative review by a panel of FDA advisers. On Wednesday, company executives doubled down on this optimism by sharing what they envision for aducanumab s launch. ....
Quote To Start The Day: Don t judge each day by the harvest you reap but by the seeds that you plant. Source: Robert Louis Stevenson One Big Thing In Fintech: Banking is one of the key drivers of economies worldwide. Core banking typically includes deposit and loan and credit processing. Read More. ....